Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis - Scorecard - MDSpire

Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis

  • By

  • Renzhu Liu

  • Lu Xiao

  • Qingzi Yan

  • Xiang Liu

  • February 2, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsTicagrelor acts as a direct antagonist of the P2Y12 receptor and inhibits ENT1, providing rapid and reversible platelet inhibition while affecting adenosine levels.
Target Population
Care Setting

Key Highlights

  • additional_highlight

Guideline-Based Recommendations

Diagnosis

    Management

    • Ticagrelor is recommended as a first-line antiplatelet agent in ACS management, with specific dosing of 90 mg twice daily.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • additional_practice

        References

        Original Source(s)

        Evaluating the Safety Profile of Ticagrelor: Insights from Literature and Database Analysis

        • by Renzhu Liu, Lu Xiao, Qingzi Yan, Xiang Liu

        • February 2, 2026

        Related Content

        Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis

        How Language Shapes Care 

        ACP examines ethical implications of calling all physicians “providers”

        Forecasting Atrial Fibrillation Following Acute Coronary Syndrome: Findings from the BACS and BAMI Studies